Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 273-227-8
CAS number: 68953-84-4
Short description of key information on bioaccumulation potential result: Two separate studies on the oral administration of different radio-labelled main constituents of 1,4-benzenediamine, N,N’-mixed Ph and tolyl derivs. to rats are available. Both studies have shown that the radioactivity is excreted primarily in the feces (≥75%). In total, 30-35% of the dosed amount enters into the gastro-intestinal tract via the biliary route. Less that 2% was excreted via the urine. About 22-24% of the ingested radioactivity was not yet excreted by the end of the experimental observation period.Short description of key information on absorption rate: Comparison of excreted radioactivity following administration of a 14C-radiolabeled main constituents of 1,4-benzenediamine, N,N’-mixed Ph and tolyl derivs. following dermal application versus intravenous dosing indicated that 60% of the dermally-applied test chemical was absorbed during the 7-day study. The bulk (> 95%) of the absorbed test chemical was excreted via the feces.
Three reliable studies (Jeffcoat, 1998a, Jeffcoat, 1998b and Hui, 1997)
are available on the toxicokinetic behaviour of the main constituents of
1,4-benzenediamine, N,N’-mixed Ph and tolyl derivs. upon administration
to rats. From a practical point of view it was not feasible to use the
multi-constituent substance as such as the testing material for these
studies since radio-labelling is required to enable the tracing of the
substances in the different excretion pathways. However, due to the
great structural similarity between the 3 main constituents of
1,4-benzenediamine, N,N’-mixed Ph and tolyl derivs. it can be assumed
that the main constituents will all have comparable toxicokinetic
behaviour. This reasoning is confirmed by the results of the two
available studies assessing the excretion pathways of orally
administered test substances, which are in good agreement with each
Discussion on bioaccumulation potential result:
Two studies (Jeffcoat, 1998a and Jeffcoat, 1998b) were performed to
assess the routes of excretion of two main constituents of
1,4-benzenediamine, N,N’-mixed Ph and tolyl derivs. – namely
N-(2-methylphenyl)-N’-phenylbenzene-1,4-diamine – upon oral
administration of the 14C-radiolabeled test substances to Sprague-Dawley
rats. Rats received a single dose of this radiolabeled component as a
solution in corn oil via oral gavage.
Urine, fecal and bile samples were collected over a period of 48 hours
following oral dosing to bile duct-cannulated animals. Results showed
that 76 to 78% of the administered radioactivity was excreted within
this 48 hour observation period. The main part, about 75% of the dosed
radioactivity is excreted in the feces. Urinary excretion consisted of
metabolites and accounted for maximally 2.5% of the total amount of
Analysis of the biliary fraction showed that 30-35% of the administered
radioactivity entered into the gastro-intestinal tract via the biliary
route. HPLC analysis of bile demonstrated that > 95% of the metabolites
excreted by this route exhibited greater polarity than the parent
compound, suggesting metabolic formation of oxidation and conjugation
products of these components.
Discussion on absorption rate:
Radio-labelled [14C] N,N’-bis(2-methylphenyl)benzene-1,4-diamine, one of
the main constituents of 1,4-benzenediamine, N,N’-mixed Ph and tolyl
derivs. was dermally and intravenously administered to female rats.
(Hui, 1997) The intravenous administration served as benchmark for 100%
absorption of test material. Collection of urinary and fecal excretion
over a period of 168h after dosing demonstrated 70% recovery of
radioactivity following intravenous dosing whereas a recovery of 88% of
dermally-applied test compound was achieved. The latter included skin
site rinses, tape stripping and skin digestion samples to recover
unabsorbed topically-applied residues. Comparison of excreted
radioactivity from groups of rats following dermal application versus
intravenous dosing indicated 60% of the dermally-applied test chemical
was absorbed during the 7-day study. The bulk (>95%) of absorbed test
chemical was excreted via the feces. Percutaneous uptake of chemicals by
rats is known to be substantially higher than that for primates and
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
På den här webbplatsen används kakor. Syftet är att optimera din upplevelse av den.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again